With the downfall of Covid-19, pharmaceutical companies turned to oncology in search for their next growth story. Earlier in ...

Reactogenicity is comparable for simultaneous and sequential administration of mRNA COVID-19 and influenza vaccines.

Expects to complete enrollment of the 400-participant sentinel cohort for the COVID-19 Phase 2b study in November 2024 Solid financial position enables Vaxart to attain multiple regulatory and ...

Pfizer and Moderna are hustling to develop an mRNA bird flu vaccine, the same technology used in the companies' respective COVID-19 vaccines.

Novavax Inc (NVAX) reports increased product sales and a strong cash position, while revising revenue guidance and navigating ...

Q3 2024 Earnings Call Transcript November 12, 2024 Operator: Good afternoon and welcome everyone to the GeoVax Third Quarter 2024 Corporate Update Call. My name is Michelle and I will facilitate today ...

We initiated our '24-'25 COVID-19 commercial season in mid-September shortly after achieving ... Novavax is demonstrating the ...

BioNTech said that BNT327 has the "potential to replace current checkpoint inhibitor standard of care treatments for solid ...

The virus takes control of three key host proteins that suppress the activity of the complement system. Researchers at the ...

In addition, annual estimates of RSV-associated ICU admissions ranged from 24,400 to 34,900 for the 2016-2017 and 2017-2018 ...

A groundbreaking study introduces stable inhalable mRNA treatment using nanoparticles that hold up during nebulization, ...